ORBIMED ADVISORS LLC 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-16 8:29 pm Unchanged |
2024-09-12 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,562,971 9.000% |
0 (Unchanged) |
Filing |
| 2024-07-18 5:33 pm Sale |
2024-07-16 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,562,971 11.700% |
-56,164 (-0.74%) |
Filing |
| 2023-03-29 5:24 pm Unchanged |
2023-03-27 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,619,135 13.400% |
0 (Unchanged) |
Filing |
| 2022-12-28 5:14 pm Purchase |
2022-12-23 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,619,135 15.400% |
137,931 (+1.84%) |
Filing |
| 2022-08-18 4:39 pm Purchase |
2022-08-16 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 7,481,204 19.900% |
3,690,000 (+97.33%) |
Filing |
| 2021-02-22 6:31 pm Purchase |
2021-02-09 | 13D | Terns Pharmaceuticals, Inc. TERN |
ORBIMED ADVISORS LLC | 3,791,204 15.100% |
3,791,204 (New Position) |
Filing |